Nature: What are the different rates of blood cancer in different populations?

At present, it is not clear to what extent the biology of tumor occurrence and aging is shaped by differences in human populationsAs you age, hematopoietic cloning with acquired mutations becomes common, which can lead to blood cancerrecently, based on 33,250 autosomal mosaic chromosomal changes, researchers described generic and population-specific genomic mutations and cloning selection characteristics in hematopoietic cellsThe researchers examined 179,417 Japanese participants in the BioBank Japan queue and compared similar data with the UK Biobankin this long-lived Japanese population, researchers detected mosaic chromosomal changes in more than 35.0 percent (s.e.m., 1.4 percent) of individuals over the age of 90, suggesting an inevitable trend in cloning as they ageJapanese and Europeans showed key differences in the genomic mutation locations of their own hematopoietic clones; these differences predicted the relative incidence of chronic lymphocytic leukemia (more common in Europeans) and T-cell leukemia (more common in Japanese)three different precursors of chronic lymphocytic leukemia (including the loss of chromosomes 12 triastic, 13q, and 13q, and replication neutral loss of heteroconity) 2-6 times lower in Japanese individuals, suggesting that there were differences in cloned selection pressures in japanese and European populations, which predate clinically the emergence of chronic lymphocytic leukemiaJapanese and British populations also showed very different cloning rates for B-cell-to-T cell lines, indicating the relative ratio of B-cell and T-cell cancers in these populationsresearchers also found six previously undescribed sites where genetic variation can lead to mosaic chromosomal changes to repeat or remove genetic risk allele genes, including NBN, MRE11, and CTU2,28-91therefore, the researchers believe that the pressure of cloning selection is regulated by factors specific to the human populationTherefore, it is necessary to carry out further genomic profiling of cloning choices and cancer in populations around the world